Objective

To summarize recent scientific advances in protein-derived soluble biomarkers of osteoarthritis.

Design

A systematic search on the PubMed electronic database of clinical studies on protein-derived soluble biochemical markers of osteoarthritis in humans that were published between January 1st 2020 and March 31th 2021. The studies were selected on the basis of objective criteria and summarized in a table. Then they were described in a narrative review.

Results

Out of 1971 publications, 48 fulfilled all selection criteria and 16 were selected by the author for the narrative review. The papers were classified according their clinical significance as defined in the BIPEDS classification. Two papers investigated the “burden of disease”, two were dedicated to “investigative biomarkers”, four papers question the “prognosis”, three the “efficacy of treatment” and five the “diagnosis and phenotyping” value of protein-derived biomarkers.

Conclusions

Currently, biomarkers research is focused on their use as tools to identify molecular endotypes and clinical phenotypes and to facilitate patient screening and monitoring in clinical trials. This approach should allow a more targeted management of patients suffering from osteoarthritis.

中文翻译：

---

2021 年骨关节炎：生化标志物

客观的

总结蛋白质衍生的骨关节炎可溶性生物标志物的最新科学进展。

设计

对 2020 年 1 月 1 日至 2021 年 3 月 31 日期间发表的关于人类骨关节炎的蛋白质衍生可溶性生化标志物临床研究的 PubMed 电子数据库进行系统搜索。这些研究是根据客观标准选择的，并总结在一个表格中。然后在叙述性评论中对它们进行了描述。

结果

在 1971 篇出版物中，有 48 篇符合所有选择标准，16 篇被作者选中进行叙述性审查。这些论文根据 BIPEDS 分类中定义的临床意义进行分类。两篇论文调查“疾病负担”，两篇致力于“研究性生物标志物”，四篇论文质疑“预后”，三篇关于“治疗效果”，五篇关于蛋白质衍生生物标志物的“诊断和表型”价值。

结论

目前，生物标志物研究的重点是用作识别分子内型和临床表型的工具，并促进临床试验中的患者筛查和监测。这种方法应该允许对患有骨关节炎的患者进行更有针对性的管理。